Back to All Combinations

NTRK Fusion

Good Prognosis
0.50% Prevalence Level 1 Rare Fusions
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
NTRK1 NTRK2 NTRK3
Treatment Implications

Rare but dramatic responses >75% ORR. Tumor-agnostic approval.

Recommended Treatments
Larotrectinib
Entrectinib
Repotrectinib
Treatments to Avoid

No specific contraindications noted

Study References

NAVIGATE, STARTRK-2

Key Statistics
0.50%
Prevalence in CRC
Yes
Targetable
Clinical Notes
More common in MSI-H tumors.
Information

Category: Rare Fusions

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.